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MaOBJECTIVES This study sought to conﬁrm that the short-term hemodynamic effectiveness of the Melody transcatheter
pulmonary valve (TPV) (Medtronic, Inc., Minneapolis, Minnesota) achieved by real-world providers is equivalent to
the historical results established in the initial 5-center Investigational Device Exemption trial.
BACKGROUND TPV replacement has been used to treat right ventricular outﬂow tract (RVOT) conduit dysfunction for
>10 years. The Melody TPV received U.S. Food and Drug Administration approval in 2010 as a Humanitarian Use Device.
METHODS Patients with dysfunctional RVOT conduits were entered in this prospective, nonrandomized study at 10
centers. The primary endpoint was acceptable hemodynamic function at 6 months post-implantation, deﬁned as a
composite of RVOT echocardiographic mean gradient #30 mm Hg, pulmonary regurgitation less than moderate as
measured by echocardiography, and freedom from conduit reintervention and reoperation.
RESULTS Cardiac catheterization was performed in 120 patients for potential implantation of the Melody TPV; of these,
100 patients were implanted, with a 98.0% procedural success rate. There were no procedure-related deaths. Accept-
able hemodynamic function at 6 months was achieved in 96.7% of patients with evaluable data (87.9% of the entire
implanted cohort), with results maintained through 1 year. No patient had moderate or severe pulmonary regurgitation
after implantation. No patient required catheter reintervention in the ﬁrst year after implantation, and 2 patients required
reoperation for conduit replacement. The rate of freedom from TPV dysfunction was 96.9% at 1 year.
CONCLUSIONS This ﬁrst prospective, real-world experience with the Melody TPV in the United States demonstrates
continued high procedural success, excellent short-term TPV function, and low reintervention and reoperation rates
at 1 year. (Melody Transcatheter Pulmonary Valve Post-Approval Study; NCT01186692) (J Am Coll Cardiol Intv
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AB BR E V I A T I O N S
AND ACRONYM S
IDE = Investigational Device
Exemption
NYHA = New York Heart
Association
PR = pulmonary regurgitation
RV = right ventricular
RVOT = right ventricular
outﬂow tract
RV-PA = right ventricular–to–
pulmonary artery
SAE = serious adverse event(s)
TPV = transcatheter
onary valve
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1255development of calciﬁcation, intimal proliferation,
and graft degeneration. Conduit stenosis and insufﬁ-
ciency place a pressure and volume load, respec-
tively, on the right ventricle, predisposing the
patient to the development of right ventricular (RV)
systolic and diastolic dysfunction, dilation, and tri-
cuspid regurgitation. These changes in the right
ventricle in turn can lead to arrhythmias, exercise
intolerance, and risk of sudden death (1). Restoring
RVOT function can result in improved RV size and ex-
ercise tolerance, as well as decreased risk of arrhyth-
mias (1,2). Multiple RVOT conduit reoperations to
restore RVOT function are needed over the course of
a patient’s lifetime due to conduit degeneration (3),
and subsequent conduits can have shorter durations
of freedom from failure compared with original con-
duits (4).SEE PAGE 1263Transcatheter pulmonary valve (TPV) implantation
with a stent-mounted bovine jugular venous valve
was ﬁrst reported in an RVOT conduit in 2000 as
a means of delaying eventual surgical conduit re-
placement (5) and has more recently been reported
elsewhere (6–8). The Melody TPV (Medtronic, Inc.,
Minneapolis, Minnesota) was studied initially in the
United States in a 5-center Investigational Device
Exemption (IDE) protocol (no. G050186). A total of
150 patients with dysfunctional RVOT conduits were
enrolled between January 2007 and January 2010.
Patients who underwent Melody TPV placement
experienced signiﬁcant improvement in pulmonary
regurgitation (PR), RV systolic pressure, and New
York Heart Association (NYHA) functional class with
relatively uncommon serious adverse events (SAE)
(9). The Melody TPV was then approved by the U.S.
Food and Drug Administration as a Humanitarian
Use Device in January 2010 to treat dysfunctional
circumferential RVOT conduits that were $16 mm
at initial implantation. Humanitarian Use Device
approval required that a post-approval study be per-
formed to conﬁrm the results of the IDE trial in 10 U.S.
centers to which the therapy was new. We describe
here the initial results of the post-approval study
with 1-year outcomes.
METHODS
STUDY DESIGN. The U.S. Melody Transcatheter Pul-
monary Valve Post-Approval Study is an ongoing,
prospective, nonrandomized, historically controlled
study designed to conﬁrm that the short-term he-
modynamic effectiveness of implantation of the
Melody TPV in 100 patients with dysfunctional RVOTconduits is noninferior to the results ob-
tained in the IDE trial. Patient selection was
based on speciﬁc criteria used in the IDE trial
but did not include the age (5 years of age
and older) and weight ($30 kg) limitations.
Key inclusion criteria included patients
eligible for a Melody TPV (dysfunctional
conduit $16 mm when originally implanted:
moderate or greater regurgitation and/or
stenosis with a mean RVOT gradient $35
mm Hg by transthoracic echocardiography).
Key exclusion criteria included use in the
aortic or mitral position and active endo-
carditis. All patients meeting selection criteria
were offered enrollment consecutively until
the maximal number of implants (15 per center) was
reached. It is possible that a few eligible patients may
not have agreed to study enrollment because partici-
pation was voluntary. At each center, participating
implanters were proctored on w5 implants before
study implantations were started. A variable number
of commercial implantations may have been per-
formed before the initiation of the study or during the
study period in patients whowere either not eligible to
participate or who elected not to participate. Enroll-
ment ranged from 3 to 21 patients per site, with im-
plantations ranging from 3 to 15 per site. The primary
objective was to conﬁrm that the short-term hemo-
dynamic effectiveness of implantation of the Melody
TPV achieved by real-world providers is equivalent to
the historical control established in the 5-center
IDE study. Evaluation time points were discharge,
6 months and 1 year post-implantation, and annually
for 5 years or until TPV explantation. SAE were
deﬁned according to International Organization for
Standardization 14155 (10). The study was approved
by the institutional review board at each institution,
and written informed consent was obtained from pa-
tients and/or guardians before the catheterization.
The U.S. Melody Transcatheter Pulmonary Valve Post-
Approval Study was designed and funded by the study
sponsor (Medtronic, Inc.), which was responsible for
selection of the study sites, monitoring of data, man-
agement of case report forms, and statistical analyses.
The study investigators made the decision to write
this paper and agreed on the submitted version.
OUTCOME MEASURES. The primary outcome mea-
sure of acceptable valve hemodynamic function at 6
months post-implantation was determined for pa-
tients with the TPV implanted for >24 h and as a
composite of the following: mean RVOT gradient #30
mm Hg by continuous-wave Doppler recording on
transthoracic echocardiography, severity of conduit
pulm
TABLE 1 Secondary Outcome Measures
Safety
Serious procedure-related adverse events
Serious device-related adverse events at 6 months
post-implantation
Incidence of serious device-related adverse events over the
follow-up period
Freedom from death (all-cause, procedural, and device related)
Efﬁcacy
Procedural success
TPV implanted in desired location, and
RV-PA peak-to-peak gradient <35 mm Hg, and
No more than mild PR by angiography, and
Free from explantation at 24 h post-implantation
Freedom from stent fracture
Freedom from reintervention on the TPV
Freedom from RVOT conduit reoperation
Freedom from TPV dysfunction
No more than mild PR by echocardiography
Mean RVOT gradient #40 mm Hg
Free from reintervention and RVOT conduit reoperation
Clinical utility
Changes in NYHA functional class
NYHA ¼ New York Heart Association; PR ¼ pulmonary regurgitation; RV-PA ¼
right ventricular-to-pulmonary artery; RVOT ¼ right ventricular outﬂow tract;
TPV ¼ transcatheter pulmonary valve.
TABLE 2 Demographic Data and Conduit Characteristics of 120
Patients Undergoing Catheterization (N ¼ 120)
Weight, kg 59.4  21.7 (18.6–119.0)
Sex
Male 79 (66.0)
Female 41 (34.0)
Age, yrs 19.9  9.7
Diagnosis
Tetralogy of Fallot 47 (39.2)
Absent pulmonary valve 5 (10.6)
With pulmonary stenosis 22 (46.8)
With pulmonary atresia 19 (40.4)
Atrioventricular canal 1 (2.1)
Truncus arteriosus 18 (15.0)
Ross operation 20 (16.7)
D-Transposition of the great arteries 6 (5.0)
L-Transposition of the great arteries 4 (3.3)
Isolated pulmonary stenosis 4 (3.3)
Pulmonary stenosis and ventricular
septal defect
3 (2.5)
Pulmonary atresia/intact ventricular
septum
2 (1.7)
Pulmonary atresia and ventricular
septal defect
5 (4.2)
Other 11 (9.2)
RVOT conduit type
Homograft 79 (65.8)
Biological 23 (19.2)
Bioprosthetic valve 16 (13.3)
Synthetic 2 (1.7)
RVOT conduit size, mm (N ¼ 119) 21.4  3.6
Bioprosthesis (n ¼ 16) 24.4  3.2
Conduit (n ¼ 103) 20.9  3.4
No. of previous surgical conduits
1 61 (50.8)
2 49 (40.8)
3 8 (6.7)
4 2 (1.7)
No pre-existing RVOT conduit stent 99 (82.5)
Values are mean  SD (range) or n (%).
RVOT ¼ right ventricular outﬂow tract.
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1256regurgitation less than moderate by transthoracic
echocardiography, and freedom from RVOT conduit
reoperation or catheter reintervention. Based on the
results of the IDE trial, to achieve noninferiority, the
performance goal for acceptable hemodynamic func-
tion was set at 75%. Secondary outcome measures
were intended to characterize the safety, efﬁcacy,
and clinical utility of the Melody TPV (Table 1).
ECHOCARDIOGRAPHY. Conduit mean gradients
were measured by tracing the border of the spectral
continuous-wave Doppler recording. PR was catego-
rized into none, trace, mild, moderate, and severe
by assessing the width of the color Doppler jet
compared with the conduit width and by the diastolic
color ﬂow reversal in the pulmonary arteries (11,12).
All echocardiographic data were site-reported.
CARDIAC CATHETERIZATION PROCEDURE. Patients
meeting entry criteria underwent cardiac cathe-
terization while under either general anesthesia
or conscious sedation. The peak-to-peak systolic
gradient was calculated as the difference in systolic
pressure between the RVOT and the main pulmonary
artery. The RV/aortic pressure ratio was also calcu-
lated. Angiography performed in the conduit was
used to measure the narrowest diameter of the
conduit at the site of intended implantation. Assess-
ment of coronary artery anatomy and conduitangioplasty was performed at the discretion of the
implanter. Concomitant interventional procedures
were allowed. The size of angioplasty balloons,
balloon waist size for implant, pre-stenting of the
RVOT, and post-implantation dilation were deter-
mined by the implanter.
FOLLOW-UP EVALUATION. Clinical assessment, trans-
thoracic echocardiography, and chest radiography
were performed at discharge, 6 months, and 12
months post-implantation at each implantation cen-
ter. At the 6-month visit, chest radiography included
ﬂuoroscopy.
STATISTICAL ANALYSIS. Descriptive statistics were
used to summarize the patient population and
TABLE 3 Baseline Clinical Status and Right-Heart Hemody-
namics of the 100 Patients Undergoing Attempted Melody
TPV Implantation (N ¼ 100)
NYHA functional class*
I 34 (34.0)
II 49 (49.0)
III 14 (14.0)
IV 1 (1.0)
Primary indication
Stenotic 16 (16.0)
Regurgitant 52 (52.0)
Mixed 32 (32.0)
RVOT mean gradient by echocardiography,
mm Hg (n ¼ 97)
33.3  14.1
Median (range) 34.0 (5.6–70.0)
Maximal TR velocity by echocardiography,
m/s (n ¼ 70)
3.8  0.8
Median (range) 3.9 (1.0–5.2)
Pulmonary regurgitation by echocardiography
None 2 (2.0)
Trace 6 (6.1)
Mild 7 (7.1)
Moderate 40 (40.4)
Severe 44 (44.4)
Catheterization
Peak RV-PA gradient, mm Hg 36.2  17.2
Median (range) 37.5 (3–110)
RV/aortic pressure ratio 0.7  0.2
Median (range) 0.7 (0.3–1.4)
Values are n (%), mean  SD, and median (range). *Could not be assessed in
2 patients.
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1257procedural and clinical follow-up, and echocardio-
graphic data. The number and percentage of patients
are provided for categorical variables, and continuous
variables are presented as mean  SD or median
(minimum, maximum). The exact method was used
to test the one proportion hypothesis of non-
inferiority. The Student paired t test was used to
evaluate the change in tricuspid regurgitation jet
velocity and mean RVOT gradient from pre-
implantation to 6 months and from pre-implantation
to 12 months. The Wilcoxon signed rank test was
applied to evaluate change in tricuspid regurgitation
and PR from pre-implantation to 6 months and from
pre-implantation to 12 months. A p value <0.05 was
regarded as statistically signiﬁcant, except in the
multiple comparisons of the tricuspid and pulmonary
valve hemodynamics. In these cases, the Bonferroni
method was used to adjust for the multiple compar-
isons, and the statistical signiﬁcance was set at
p value <0.0125. Kaplan-Meier analyses were per-
formed for time-to-event data, and Peto’s method
was used to calculate the SE for freedom from an
event. Factors associated with TPV dysfunction could
not be assessed appropriately due to the small num-
ber of events; therefore, Cox regression was not per-
formed. Statistical analyses were performed using
SAS software version 9.2 (SAS Institute Inc., Cary,
North Carolina).RV ¼ right ventricular; TR ¼ tricuspid regurgitation; other abbreviations as in
Table 1.RESULTS
PATIENTS. From July 2010 to July 2012, 120 patients
(79 male, 65.8%) with a mean age of 19.9  9.7 years
(range 5 to 45 years) were enrolled and underwent
catheterization for potential implantation of a Melody
TPV. Demographic data and conduit characteristics
are listed in Table 2.
PROCEDURAL OUTCOMES. Of the 120 patients un-
dergoing catheterization, TPV implantation was not
attempted in 19 patients due to the risk of coronary
artery compression (n ¼ 6), conduit not suitable for
implant (n ¼ 4), criteria for intervention not met
during catheterization (n ¼ 4), relief of conduit ste-
nosis by angioplasty (n ¼ 3), need for surgical repair
of another heart condition (n ¼ 1), and risk of branch
pulmonary artery stent compression (n ¼ 1).
TPV implantation was attempted in 101 patients
but was aborted in a 19.9-kg patient due to distal
branch pulmonary artery perforation leading to self-
resolved pulmonary hemorrhage. Implantation was
performed in 100 patients, and their baseline clinical
status and right-heart hemodynamics are summa-
rized in Table 3. The femoral venous approachwas used in 87 patients (87%) and internal jugular
venous in 13 patients (13%). Concomitant procedures
were performed in 84 of the catheterizations (84%),
including 76 procedures with conduit pre-stenting
(46 with single stents and 30 with multiple stents),
13 with balloon angioplasty of a branch pulmonary
artery, and 9 with $1 stents placed in the branch
pulmonary arteries. In patients undergoing TPV im-
plantation, the original conduit diameters ranged
from 16 to 30 mm, and the outer diameters of bio-
prosthetic valves ranged from 19 to 31 mm, based on
manufacturer sizing.
Procedure-related SAE occurred in 16 of the 120
patients (13.3%) undergoing catheterization, with 2
SAE occurring in 1 patient (Table 4). Conﬁned conduit
tear was the most common of the procedural SAE,
occurring in 5% of catheterizations. All cases were
determined to be SAE because intervention was
required, and all were treated successfully with
covered stents.
The procedural success rate (see Table 1 for deﬁ-
nition) for the 101 implantation attempts was 98%
(n ¼ 99). In addition to the previously mentioned
TABLE 4 Procedural and Device Related SAE in 120 Patients Undergoing Catheterization
No. of
Patients Complication Outcome
Procedural SAE
6 Contained conduit tear Resolved with covered stent
1 Distal PA perforation Self-resolved
1 Lower extremity peripheral neuropathy
from access site hematoma
Self-resolved
1 Pulmonary edema from mitral stenosis and
ﬂuid given during procedure
Resolved with IV diuretics during
additional hospitalization
1 Fever Resolved with 5 days of IV antibiotics
1 Minor hemorrhage at access site after
discharge
Resolved with compression and
hospitalization
1 Deep venous thrombosis Resolved with warfarin
1 Common femoral artery occlusion due
to closure device
Resolved with vascular surgery
1 Paravalvular leak Resolved with second Melody placement
1 Pulseless ventricular tachycardia 15 h
post-implantation
Resolved with cardioversion and
lidocaine
1 Ventricular tachycardia during procedure Resolved with cardioversion
1 Coronary compression with myocardial
ischemia
Resolved with surgical conduit
replacement
Device-Related SAE
3 Endocarditis All resolved with antibiotics; 1 patient
had surgery for aortic and pulmonary
valve replacement after 2 episodes of
endocarditis and aortic aneurysm
1 Sepsis Resolved with antibiotics
1 Major stent fracture (no pre-stent) Surgical conduit replacement
1 Pulmonary embolism Resolved with medical therapy
1 Palpitations Resolved spontaneously during
hospitalization for observation
1 Atrial ﬂutter Resolved with cardioversion
IV ¼ intravenous; PA ¼ pulmonary artery; SAE ¼ serious adverse events.
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1258patient with the pulmonary hemorrhage, 1 of the
implanted patients who had a Ross operation expe-
rienced left main coronary artery occlusion during
TPV implantation, despite the fact that there was no
coronary compression on balloon testing. In the
remaining 99 patients, there was no more than mild
TPV insufﬁciency by angiography, and no one had a
RV-PA peak gradient $35 mm Hg at catheterization.
6-MONTH AND 1-YEAR FOLLOW-UP. Cl in i ca l s tatus
and funct iona l capac i ty . All patients implanted
>24 h and with follow-up data were alive at 1 year.
One patient withdrew from the study at 58 days post-
implantation, and 1 patient was lost to follow-up after
the 6-month visit.
The percentage of patients in NYHA functional
class I increased from 35% at baseline to 89% at 1 year
(Figure 1). In 1 patient with NYHA functional class III
symptoms and protein-losing enteropathy pre-
implantation, class IV symptoms developed after
implantation due to progression of the severe enter-
opathy and not to TPV dysfunction.Hemodynamic resul ts and re intervent ion .
Of the 99 patients implanted for >24 h, acceptable
TPV hemodynamic function at 6 months was con-
ﬁrmed in 87 patients (96.7% of those with evaluable
echocardiographic data and 87.9% of entire cohort),
with 87 patients having a mean RVOT gradient #30
mm Hg and no patient having moderate or worse
PR, needing catheter-based reintervention, or re-
quiring surgical RVOT conduit replacement. This was
signiﬁcantly better than the study performance goal
of 75% (p < 0.0001). Adequate 6-month echocardio-
graphic data were missing for 8 patients in addition to
data for the aforementioned patient who withdrew
before the 6-month visit.
Acceptable TPV hemodynamic function at 1 year
was conﬁrmed in 82 patients (94.3% of those with
evaluable echocardiographic data and 82.8% of the
entire cohort), with 82 patients having a mean RVOT
gradient of #30 mm Hg and no patient having mod-
erate or worse PR (Figure 2). Two patients underwent
surgical conduit replacement after the 6-month visit,
one for endocarditis and the need for concomitant
aortic valve and root replacement and the other for
major stent fracture with severe stenosis. No patient
required additional catheter-based intervention. The
1-year rate of freedom from catheter- or surgery-
based reintervention was 98.0% and from TPV
dysfunction, was 96.9%, as shown in Figure 3A. The
echocardiographic mean RVOT gradient decreased
from 33.3  14.1 mm Hg pre-implantation to 15.0  9.9
and 15.1  7.1 mm Hg at 6 months and 1 year,
respectively. More than 84% of the patients had
moderate or severe PR at baseline, but no patient had
moderate or severe PR after implantation, including
at 1 year. The majority of patients had no PR
(Figure 2). In addition to improvement in PR, echo-
cardiographic tricuspid regurgitation improved
signiﬁcantly from baseline to 6 months and 1 year
(p < 0.0001).
SERIOUS ADVERSE EVENTS. Aside from procedural
events, device-related SAE occurred in 8% of patients
in the ﬁrst year of follow-up (Table 4). There were no
deaths in the ﬁrst year.
Endocard i t i s . Endocarditis was one of the most
common SAE, occurring in 3 patients in the ﬁrst year
post-implantation with a 1-year freedom from endo-
carditis rate of 97.0% (Figure 3B). The cases were
not thought to be procedure related because they
occurred 50, 56, and 132 days post-implantation,
and only 1 case was shown to have Melody TPV
involvement by echocardiography. Two cases were
due to Staphylococcus aureus and 1 to variable coc-
cobacilli. All patients were treated successfully with
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1259antibiotics, but 1 patient underwent surgery for
RVOT conduit replacement and concomitant aortic
valve and root replacement. A fourth patient had
enterococcal sepsis 58 days after implantation but did
not meet the modiﬁed Duke criteria for endocarditis
diagnosis. The patient was successfully treated with 6
weeks of antibiotics.
Stent f racture . During follow-up, stent fracture
occurred in 7 patients, with only 1 patient requiring
reintervention (deﬁned as major stent fracture) due
to severe stenosis without PR. The patient with the
major stent fracture did not have a pre-stent placed in
the homograft. The 6 patients with minor stent frac-
tures were all pre-stented, and none had TPV
dysfunction at 6-month or 1-year follow-up.FIGURE 1 New York Heart Association Functional Class
Flow diagram depicting the number of patients in each functional class and changes in
class from pre-implantation to the 6-month and 1-year follow-up evaluations.
FIGURE 2 Pulmonary Regurgitation Grades
Bar graph showing the distribution of echocardiographic pulmonary regurgitation at
baseline, discharge, 6 months, and 1 year post-transcatheter pulmonary valve
implantation.DISCUSSION
This post-approval study of the Melody TPV sub-
stantiates the ﬁndings of the 5-center IDE trial by 10
additional U.S. centers. Both studies demonstrated
the safety and hemodynamic effectiveness of the TPV
throughout the ﬁrst year after implantation.
PROCEDURAL SUCCESS. The procedural success rate
in this study was 98.0%, which was comparable to
the 100% success rate achieved in the IDE trial (9).
Our study, however, showed procedure-related SAE
in 13% of the 120 patients undergoing catheteriza-
tion, which was higher than the 6% seen in the IDE
trial. For the IDE trial, patient enrollment was
limited to those $5 years and $30 kg, and concom-
itant interventions, such as conduit bare metal
stenting and branch pulmonary artery stenting, were
not allowed in the initial 35 patients enrolled. Our
study did not have any limitations on concomitant
procedures, age, or weight. In fact, 84% of our pa-
tients underwent concomitant interventional pro-
cedures, of which 78% were stenting procedures,
whereas only 41% of the IDE patients underwent
concomitant procedures. Additional interventions
lengthen the procedure and offer more potential for
complications or adverse events to occur. Further-
more, there was no age or weight limit in our study,
and 1 of the 2 patients in whom implantation was
unsuccessful due to pulmonary hemorrhage before
implantation would have been too small to enter the
IDE trial. Detailed patient information such as the
presence of comorbidities, complete hemodynamics,
and other predictors for risk stratiﬁcation were not
collected in our study to allow a fair comparison of
the patient populations, although 15% of patients in
both studies were in NYHA functional classes III and
IV. Given the procedural restrictions and rigors of the
FIGURE 3 Freedom From Catheter Reintervention, Reoperation, and
TPV Dysfunction and Endocarditis
Kaplan-Meier curves showing freedom from catheter reintervention, reoperation, and
transcatheter pulmonary valve (TPV) dysfunction (A) and endocarditis (B).
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1260IDE study, it is expected that the real-world study
would have more procedural complications. Indeed,
our procedural SAE rate was comparable to the 14%
in the Italian multicenter prospective study in which
there was also 1 patient who required emergency
surgery (13).
Coronary arteries can run in close proximity to
RVOT conduits, and pre-implantation testing with
imaging of the coronary arteries during balloon
inﬂation in the conduit is recommended. Six patients
(5%) who underwent catheterization in our study did
not undergo implantation due to the risk of coronary
compression. This is comparable to 4.7% in a large
retrospective study by Morray et al. (14), which
included the IDE trial patients. One patient statuspost Ross operation in our study did have compres-
sion of the left main coronary artery on delivery of the
Melody TPV despite negative results on balloon
testing and no evidence of coronary compromise after
placement of 2 bare-metal stents in the RVOT homo-
graft conduit. The patient required immediate pla-
cement of a left ventricular assist device and transfer
to the operating room for surgical RVOT conduit
removal. This demonstrates the limitations of balloon
testing, as it may not always be possible to completely
predict the space effect of the implanted Melody TPV
with an angioplasty balloon. Coronary compression
from Melody TPV placement has been described and
can be catastrophic (15–17).
FOLLOW-UP RESULTS. Although there were more
procedural SAE in our study compared with the IDE
trial, the TPVs in our study had equivalent func-
tion and fewer reinterventions. The hemodynamic
outcome measured in the IDE study was freedom
from TPV dysfunction (no more than mild PR by
echocardiography, mean RVOT gradient #40 mm Hg,
and freedom from reintervention and RVOT conduit
reoperation). The rate of freedom from TPV
dysfunction at 1 year was 93.5  2.4% in the IDE trial
compared with 96.9  1.8% in our study. Although
direct statistical comparisons cannot be made be-
tween the 2 studies, presumably the higher dysfunc-
tion in the IDE trial was due to more reinterventions
with 11 of 124 (8.9%) implanted patients requiring
catheter- or surgery-based reintervention as opposed
to 3 of 100 (3.0%) in our study. The higher reinter-
vention rate in the IDE trial was due to a higher
incidence of stent fracture with freedom from all
stent fracture rates of 83.7  3.7% at 1 year (9) and
77  4% at 14 months (18) versus 92.7  2.8% at
1 year in our study. McElhinney et al. (18) found that
implantation of the Melody TPV within any intact
pre-stent was associated with longer freedom from
diagnosis of stent fracture, TPV dysfunction, and
RVOT reintervention. Our study population had a
higher incidence of concomitant pre-stenting of the
RVOT (76%) than in the IDE trial (35%), which did not
allow concomitant procedures in the ﬁrst 35 patients
(9). The improved performance of the Melody TPV in
our study may reﬂect the real-world experience of the
use of the valve over time and incorporation of
techniques such as pre-stenting to avoid early valve
dysfunction.
RVOT conduit mean gradients by echocardiogra-
phy decreased from 33.3  14.1 mm Hg at baseline to
15.0  9.9 mm Hg at 6 months in our study, which
compares favorably with 33.4  15.0 mm Hg and 20.0
 8.6 mm Hg, respectively, in the IDE trial. PR
decreased from moderate or severe in 81% of IDE
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1261patients and 84% of Post-Approval Study patients to
no more than mild in any patient in either study at 1
year (9).
Endocarditis was not reported in the short- and
medium-term outcomes of the IDE trial (9) but did
occur in 10 of 150 IDE patients all >6 months post-
implantation (442.7 patient-years of follow-up), as
reported by McElhinney et al. (19) in the combined
results of the 3 prospective North American and
European Melody TPV studies, which included this
Post-Approval Study. Meeting endocarditis criteria
in that combined study only required that a patient
be febrile and have a positive blood culture with an
organism known to cause endocarditis. Evidence of
vegetation or valve dysfunction was not required.
The combined study showed an annualized rate of a
ﬁrst episode of 2.4% (95% conﬁdence interval: 1.4% to
3.8%) per patient-year with a median duration from
implantation to diagnosis of 1.3 years (range, 50 days
to 4.7 years) (19). Using the deﬁnition of endocarditis
based only on fever and positive blood culture, 4 pa-
tients in our study would meet these criteria with
infection occurring at 50, 56, 58, and 132 days post-
implantation. When considering only those with TPV
vegetation or new or progressive TPV dysfunction in
addition, then the annualized rate for a ﬁrst episode
was 0.88% in the combined study (95% conﬁdence
interval: 0.32% to 1.9%) per patient-year. The true
incidence of endocarditis in surgically placed RVOT
prostheses in patients with congenital heart disease is
unknown, and available data are based on case series,
which show a total incidence ranging from 0.5% to
5.9% and may be fraught with underreporting (19).
The incidence of endocarditis in our present study is
comparable to the incidence seen in left heart pros-
thetic valves of 3.1% at 12 months (20). It is unknown
whether there are unique features of the RVOT
conduit, such as calciﬁcation, or of the Melody TPV
itself that may predispose to endocarditis, but
extenuating circumstances, such as a history of
endocarditis, open oral or skin lesions, or preceding
dental cleaning were present in nearly two-thirds of
the cases in the combined study (19).STUDY LIMITATIONS. First, a core lab was not used to
review the hemodynamic and echocardiographic
data. These data were interpreted at the individual
institutions. Second, due to the small number of
events of TPV dysfunction, a Cox regression analysis
to identify factors associated with TPV dysfunction
could be biased and was not performed. Lastly, our
study did not have age, weight, or concomitant
intervention limitations, as the IDE trial did, making
direct comparisons of procedural success and SAE
between the 2 studies difﬁcult.CONCLUSIONS
This is the ﬁrst prospective, multicenter post-
approval study in the United States of the Melody
TPV in the treatment of dysfunctional RVOT con-
duits. It conﬁrms the strong performance of the
Melody TPV achieved by real-world providers with
results comparable to those of the U.S. IDE trial.
Although continued follow-up is needed to determine
the signiﬁcance and risk factors for stent fractures
and endocarditis in this population, the study met its
primary objective of noninferiority to the IDE trial
results at 6 months. With a high procedural success
rate, excellent hemodynamic function at 6 and 12
months, and relatively low rates of SAE, the Melody
TPV remains a less invasive alternative to surgical
RVOT conduit replacement. Delaying surgery may
help to decrease the total number of open heart sur-
geries required in a lifetime.
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